- Preclinical data showed strong T-cell responses for IO102-IO103 vaccine.
- IO170 demonstrated significant tumor growth inhibition in multiple cancer models.
- Both vaccines successfully modulated the tumor microenvironment.
IO Biotech (IOBT, Financial), a clinical-stage biopharmaceutical company, has presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The company showcased promising results for its two cancer vaccine candidates, IO102-IO103 and IO170, both developed through its proprietary T-win® platform.
IO102-IO103, a dual-antigen vaccine targeting IDO1+ and PD-L1+ cells, demonstrated significant T-cell responses and unique modulation of the tumor microenvironment in mouse models. This vaccine exhibited molecular changes not observed with conventional PD-1 or PD-L1 inhibitors, suggesting a potentially synergistic mechanism of action.
Simultaneously, IO170, which targets Transforming Growth Factor beta (TGF-?), showed significant inhibition of tumor growth in breast and prostate cancer models. The preclinical studies revealed an increase in CD8+ T-cell density and a reduction in suppressive cells like M2 macrophages, effectively reshaping the tumor microenvironment to enhance immune activation.
These findings further reinforce the potential of IO Biotech's vaccine candidates in enhancing anti-tumor immunity by targeting multiple facets of the tumor microenvironment. The company's expansion of its pipeline, including the lead investigational vaccine IO102-IO103, continues to progress in clinical trials, with promising early results.
